Abstract
Candida species are major causes of mucosal and invasive infections, leading to substantial morbidity and mortality. Despite the development of new classes of antifungal drugs, mortality in patients with systemic candidiasis remains high. Host-Candida interaction plays an important role in effective elimination of the pathogen. Genetic studies have rendered important insights into antifungal host defense and have identified potential targets for adjunctive therapy. In this article, the authors review the genetic variations in the host defense to Candida and their implications for the treatment of mucosal and systemic candidiasis.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antifungal Agents / therapeutic use*
-
CARD Signaling Adaptor Proteins / immunology
-
Candida / immunology
-
Candida / pathogenicity*
-
Candidiasis / drug therapy*
-
Candidiasis / genetics*
-
Candidiasis / immunology
-
Candidiasis / microbiology
-
Cytokines / immunology
-
Disease Susceptibility / immunology
-
Disease Susceptibility / microbiology
-
Genetic Predisposition to Disease
-
Genetic Variation
-
Granulomatous Disease, Chronic / genetics
-
Granulomatous Disease, Chronic / microbiology
-
Host-Pathogen Interactions
-
Humans
-
Lectins, C-Type / immunology
-
Mannose-Binding Lectins / immunology
-
Toll-Like Receptors / immunology
Substances
-
Antifungal Agents
-
CARD Signaling Adaptor Proteins
-
CARD9 protein, human
-
CLEC7A protein, human
-
Cytokines
-
Lectins, C-Type
-
Mannose-Binding Lectins
-
Toll-Like Receptors